Myriad Genetics, Inc.
MYGN today announced that results from a verification study showed
the Myriad myPath™ Melanoma test effectively differentiated malignant melanoma
from benign skin lesions. The clinically-actionable information provided by
myPath Melanoma will empower healthcare providers with objective data and
improve the diagnosis of patients with melanoma. Myriad presented these data
at the American Society of Dermatopathology Annual Meeting on Oct. 13, 2013.
The verification study evaluated a 23-gene panel designed to differentiate
malignant melanoma from benign skin lesions. The study analyzed 464 skin
biopsy samples including 254 samples representing melanomas from all major
subtypes including superficial spreading, lentigo maligna melanoma, acral,
nodular and desmoplastic lesions. Using this set of patient samples, the
myPath Melanoma test demonstrated high sensitivity of 89 percent and
specificity of 93 percent at differentiating malignant melanoma from benign
skin lesions.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in